Literature DB >> 16377714

In vitro activity of fosfomycin against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures.

M de Cueto1, L López, J R Hernández, C Morillo, A Pascual.   

Abstract

The agar dilution, broth microdilution, and disk diffusion methods were compared to determine the in vitro susceptibility of 428 extended-spectrum-beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin. Fosfomycin showed very high activity against all ESBL-producing strains. Excellent agreement between the three susceptibility methods was found for E. coli, whereas marked discrepancies were observed for K. pneumoniae.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16377714      PMCID： PMC1346795          DOI： 10.1128/AAC.50.1.368-370.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients.

Authors:  Jesús Rodríguez-Baño; Maria Dolores Navarro; Luisa Romero; Luis Martínez-Martínez; Miguel A Muniain; Evelio J Perea; Ramón Pérez-Cano; Alvaro Pascual
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

2.  High levels of antimicrobial coresistance among extended-spectrum-beta-lactamase-producing Enterobacteriaceae.

Authors:  Mitchell J Schwaber; Shiri Navon-Venezia; David Schwartz; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

3.  Identification and broad dissemination of the CTX-M-14 beta-lactamase in different Escherichia coli strains in the northwest area of Spain.

Authors:  German Bou; Monica Cartelle; Maria Tomas; Delia Canle; Francisca Molina; Rita Moure; Jose Maria Eiros; Antonio Guerrero
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

4.  Fosfomycin tromethamine susceptibility of outpatient urine isolates of Escherichia coli and Enterococcus faecalis from ten North American medical centres by three methods.

Authors:  P C Fuchs; A L Barry; S D Brown
Journal:  J Antimicrob Chemother       Date:  1999-01       Impact factor: 5.790

5.  In-vitro activity of fosfomycin against vancomycin-resistant enterococci.

Authors:  F Allerberger; I Klare
Journal:  J Antimicrob Chemother       Date:  1999-02       Impact factor: 5.790

6.  [Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in spanish hospitals (GEIH-BLEE Project 2002)].

Authors:  José Ramón Hernández; Alvaro Pascual; Rafael Cantón; Luis Martínez-Martínez
Journal:  Enferm Infecc Microbiol Clin       Date:  2003-02       Impact factor: 1.731

7.  Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia.

Authors:  D L Paterson; L Mulazimoglu; J M Casellas; W C Ko; H Goossens; A Von Gottberg; S Mohapatra; G M Trenholme; K P Klugman; J G McCormack; V L Yu
Journal:  Clin Infect Dis       Date:  2000-03       Impact factor: 9.079

8.  In-vitro susceptibility of quinolone-resistant clinical isolates of Escherichia coli to fosfomycin trometamol.

Authors:  D Ungheri; E Albini; G Belluco
Journal:  J Chemother       Date:  2002-06       Impact factor: 1.714

9.  In vitro susceptibility testing procedures for fosfomycin tromethamine.

Authors:  A L Barry; P C Fuchs
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

Review 10.  Why fosfomycin trometamol as first line therapy for uncomplicated UTI?

Authors:  G C Schito
Journal:  Int J Antimicrob Agents       Date:  2003-10       Impact factor: 5.283
View more
  28 in total

1.  Fosfomycin for the treatment of drug-resistant urinary tract infections: potential of an old drug not explored fully.

Authors:  Vrushali Patwardhan; Sarman Singh
Journal:  Int Urol Nephrol       Date:  2017-06-14       Impact factor: 2.370

Review 2.  Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

Review 3.  Fosfomycin: an old, new friend?

Authors:  M Popovic; D Steinort; S Pillai; C Joukhadar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-14       Impact factor: 3.267

4.  In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin.

Authors:  Andrea Endimiani; Gopi Patel; Kristine M Hujer; Mahesh Swaminathan; Federico Perez; Louis B Rice; Michael R Jacobs; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2009-11-09       Impact factor: 5.191

5.  Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods.

Authors:  Ching-Lan Lu; Chia-Ying Liu; Yu-Tsung Huang; Chun-Hsing Liao; Lee-Jene Teng; John D Turnidge; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

Review 6.  Clinical management of infections caused by multidrug-resistant Enterobacteriaceae.

Authors:  Mercedes Delgado-Valverde; Jesús Sojo-Dorado; Alvaro Pascual; Jesús Rodríguez-Baño
Journal:  Ther Adv Infect Dis       Date:  2013-04

Review 7.  The continuing challenge of ESBLs.

Authors:  Federico Perez; Andrea Endimiani; Kristine M Hujer; Robert A Bonomo
Journal:  Curr Opin Pharmacol       Date:  2007-09-17       Impact factor: 5.547

8.  Activity of Fosfomycin against Extended-Spectrum-β-Lactamase-Producing Uropathogens in Patients in the Community and Hospitalized Patients.

Authors:  Katherine Linsenmeyer; Judith Strymish; Susan Weir; Gretchen Berg; Stephen Brecher; Kalpana Gupta
Journal:  Antimicrob Agents Chemother       Date:  2015-11-23       Impact factor: 5.191

9.  Determination of susceptibility to fosfomycin and tigecycline of Enterobacteriaceae, particularly Escherichia coli isolates, producing extended-spectrum β-lactamases from multiple regional Canadian hospitals.

Authors:  Carlee Beuk; Christian Hill; Sue Whitehead; Edith Blondel-Hill; Ken Wagner; Naowarat Cheeptham
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

10.  Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin.

Authors:  M E Falagas; M D Kanellopoulou; D E Karageorgopoulos; G Dimopoulos; P I Rafailidis; N D Skarmoutsou; E A Papafrangas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01-23       Impact factor: 3.267
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.